Compare CXM & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXM | NNNN |
|---|---|---|
| Founded | 2009 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2021 | N/A |
| Metric | CXM | NNNN |
|---|---|---|
| Price | $5.48 | $9.39 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.28 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 44.9K |
| Earning Date | 06-03-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $857,200,000.00 | N/A |
| Revenue This Year | $2.52 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | ★ $275.00 | $446.57 |
| Revenue Growth | ★ 7.64 | N/A |
| 52 Week Low | $4.72 | $10.50 |
| 52 Week High | $9.40 | $55.65 |
| Indicator | CXM | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 23.86 |
| Support Level | $5.14 | N/A |
| Resistance Level | $5.60 | $30.21 |
| Average True Range (ATR) | 0.19 | 2.12 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 82.21 | 17.53 |
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).